By Allison Cerra
DEERFIELD, Ill. (Dec. 10) Walgreens Specialty Pharmacy, a subsidiary of Walgreens, was chosen to participate in the “Therapy Optimization in Multiple Sclerosis” study, a two-year medical research study sponsored by Teva Neuroscience.
The goal of the study is to demonstrate how a specialty pharmacy-based therapy management program affects adherence, persistency and patient outcomes. Targeted patient outcomes will include relapses, disability progression, quality of life and the ability to perform work and daily activities. Approximately 3,000 patients from Walgreens and other participating specialty pharmacies will be recruited for the study.
“We are honored to participate in the TOP MS Study,” said Ray Tancredi, senior director of trade account management for Walgreens Specialty Pharmacy. “We support efforts to measure outcomes that lead to more effective MS care. Walgreens is committed to this study and to the many patients who rely on us to provide timely medication fulfillment and clinical assistance.”
Walgreens Specialty Pharmacy’s Care team of pharmacists, nurses and care coordinators provides MS patients with personalized support and education to help them get the best results from their therapy. This extensive network of specially trained clinicians helps patients face the many challenges, including side effects, that can make it difficult to stay on track with their medications. Walgreens therapy-specific clinical management programs are designed with those challenges in mind.
“Teva Neuroscience has initiated the TOP MS Study in order to enhance our understanding of issues facing MS patients, which further demonstrates our commitment to the MS community,” said MerriKay Oleen-Burkey, project leader, TOP MS Study, Teva Neuroscience. “Walgreens has been selected to partner with Teva Neuroscience on this study, due to its outstanding commitment to MS therapy management.”
People interested in participating in the study can contact Christina Makowski, Walgreens study manager, at 412-250-4703 or Christina.Makowski@Walgreens.com. – Article source: Drugstore News